Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study

Background: The basal–bolus insulin regimen is recommended in hospitalized patients with diabetes mellitus (DM), but has an increased risk of hypoglycemia. We aimed to compare dipeptidyl peptidase 4 inhibitors (DPP4-i) and basal–bolus insulin glycemic outcomes in hospitalized type 2 DM patients. Methods and patients: Our prospective randomized study included 102 elderly T2DM patients (82 ± 9 years, HbA1c 6.6% ± 1.9). Glycemic control: A variability coefficient assessed by continuous glucose monitoring (Free Style® sensor), mean insulin dose and hypoglycemia rates obtained with the two treatments were analyzed. Results: No differences were found between groups in glycemic control (mean daily glycemia during the first 10 days: 152.6 ± 38.5 vs. 154.2 ± 26.3 mg/dL; p = 0.8). The total doses Kg/day were 0.40 vs. 0.20, respectively (p < 0.001). A lower number of hypoglycemic events (9% vs. 15%; p < 0.04) and lower glycemic coefficient of variation (22% vs. 28%; p < 0.0002) were observed in the basal–DPP4-i compared to the basal–bolus regimen group. Conclusions: Treatment of inpatient hyperglycemia with basal insulin plus DPP4-i is an effective and safe regimen in old subjects with T2DM, with a similar mean daily glucose concentration, but lower glycemic variability and fewer hypoglycemic episodes compared to the basal bolus insulin regimen.

• Publication year

  2022

• Venue

  Journal of Clinical Medicine

• Publication date

  2022-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/jcm11102813PMID 35628938PMCID 9143484
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021.

  2021cited by this paper
• Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

  2019cited by this paper
• Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study

  2019cited by this paper
• Early Intervention for Diabetes in Medical and Surgical Inpatients Decreases Hyperglycemia and Hospital-Acquired Infections: A Cluster Randomized Trial

  2019cited by this paper
• Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study)

  2018cited by this paper
• Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.

  2017cited by this paper
• Glucose Management in Hospitalized Patients.

  2017cited by this paper
• Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

  2015cited by this paper
• Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients

  2013cited by this paper
• Glycemic Variability in Hospitalized Patients: Choosing Metrics While Awaiting the Evidence

  2013cited by this paper
• Hypoglycemia: The neglected complication

  2013cited by this paper
• Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes

  2012cited by this paper
• Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.

  2012cited by this paper
• Clinical Interpretation of Indices of Quality of Glycemic Control and Glycemic Variability

  2011cited by this paper
• Randomized Study of Basal-Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery)

  2011cited by this paper
• Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

  2011cited by this paper
• Glucose variability; does it matter?

  2010cited by this paper
• American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control

  2009cited by this paper
• American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.

  2009cited by this paper
• Glycemic Variability: The Third Component of the Dysglycemia in Diabetes. Is it Important? How to Measure it?

  2008cited by this paper
• Variability of Blood Glucose Concentration and Short-term Mortality in Critically Ill Patients

  2006cited by this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2003cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2002cited by this paper
• Standards of Medical Care in Diabetes — 2021

  year unknowncited by this paper

• Time in ranges and glucose variability in patients with type 2 diabetes on different regimens of insulin therapy

  2025cites this paper
• How Would You Treat This Inpatient With Type 2 Diabetes Mellitus? Grand Rounds Discussion From Beth Israel Deaconess Medical Center

  2024cites this paper
• Treatment adherence and the contemporary approach to treating type 2 diabetes mellitus.

  2024cites this paper
• A dipeptidil-peptidáz-4-gátlók szerepe a 2-es típusú diabetes mellitus kezelésében napjainkban

  2023cites this paper
• Hypoglycemia in patients with type 2 diabetes mellitus during hospitalization: associated factors and prognostic value

  2023cites this paper
• Safety and efficacy of non-insulin therapy in non-critically ill hospitalized patients with type 2 diabetes mellitus.

  2023cites this paper
• Kontinuität und Wandel in der Diabetestherapie

  2023cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

  2022cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2022cites this paper